ROCKVILLE, Md., Aug. 19, 2014 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing
novel anti-infective biologic and drug programs targeting specific
pathogens that cause serious infections and diseases, announced
today that its novel C. difficile development program will
be highlighted at the 54th Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.
Synthetic Biologics' Senior Vice President, Research &
Development, Mike Kaleko, M.D.,
Ph.D., will present a late-breaking poster related to the Company's
C. difficile program. The poster will be available for
viewing in Exhibit Hall A on Saturday,
September 6, from 12:00pm to 2:00pm
Eastern Time, as part of the "Agents Targeting
Clostridium difficile" session.
Title: P4A, a Novel Oral Beta-Lactamase for the Prevention of
Cephalosporin-Induced C. difficile
Infection
Authors1: M. Kaleko, J. A. Bristol, S. Connelly, P. Koski
Poster: F-250c
"We are thrilled to have the opportunity to present research
from our novel C. difficile program at ICAAC. This
conference is known for its high academic standards and draws the
infectious disease field's foremost leaders. We look forward to
presenting our findings that support the development of our
prophylactic to protect the GI microflora from the effects of
certain IV antibiotics for the prevention of C. difficile
infection," stated Jeffrey Riley,
Chief Executive Officer of Synthetic Biologics. "This scientific
presentation is very relevant, as we continue to advance our
innovative C. difficile program toward clinical trials
during 2014."
The Company previously announced that Synthetic Biologics'
academic collaborator, Jennifer
Maynard, Ph.D., of The University of
Texas at Austin's McKetta Department of Chemical Engineering
will highlight Synthetic Biologics' SYN-005 monoclonal antibody
(mAb) combination for the treatment of Pertussis (whooping cough)
in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the
"Neonatal Infections and the Case for Maternal Immunization"
session.
Title: Rational Design of Antibody Cocktails to Treat Disease
Caused by Bordetellae
Authors: M. Kaleko1, A.
Nguyen2, E. Wagner2, J. Laber2, L.
Goodfield3, W. Smallridge3, E. T. Harvill3, R. F. Wolf4, J. C. Papin4, J. A. Maynard2
1Synthetic Biologics, Rockville, MD, 2Universty of
Texas at Austin, Austin,
TX, 3Penn State Univ., University Park, PA, 4Univ. of
Oklahoma Hlth. Sci. Ctr., Oklahoma City,
OK
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology
company focused on the development of novel anti-infective biologic
and drug candidates targeting specific pathogens that cause serious
infections and diseases. The Company is developing an oral biologic
to protect the gastrointestinal microflora from the effects of IV
antibiotics for the prevention of Clostridium difficile (C.
difficile) infection, an oral treatment to reduce the impact of
methane producing organisms on constipation-predominant irritable
bowel syndrome (C-IBS), a series of monoclonal antibodies for the
treatment of Pertussis and Acinetobacter infections, and a
biologic targeted at the prevention and treatment of a root cause
of a subset of IBS. In addition, the Company is developing an oral
estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic
Biologics' current expectations and projections about future
events. In some cases forward-looking statements can be identified
by terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding Synthetic Biologics'
continued advancement of its C. difficile program toward clinical
trials. The forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from those set forth or implied by any forward-looking statements.
Important factors that could cause actual results to differ
materially from those reflected in Synthetic Biologics'
forward-looking statements include, among others, the additional
clinical studies and results not meeting expectations and other
factors described in Synthetic Biologics' report on Form 10-K for
the year ended December 31, 2013 and
any other filings with the SEC. The information in this release is
provided only as of the date of this release, and Synthetic
Biologics undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Logo -
http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
SOURCE Synthetic Biologics, Inc.